Veklury Lyophilised Powder For Iv Infusion 100 Mg 100 mg/20 ml (5 mg/ml) Powder for Injection
PDF Leaflet Revision Date: 17 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of COVID-19 in adults with pneumonia requiring supplemental oxygen.
Dosage (summary)
Day 1: 200 mg IV loading dose; Day 2-10: 100 mg IV daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Limited data; avoid in first trimester; consider in second/third trimester. Do not breastfeed.
Key Drug Interactions
- Coadministration with chloroquine or hydroxychloroquine not recommended.
Contraindications
- Hypersensitivity to remdesivir or excipients.
Common side effects
- Nausea
- Increased transaminases
- Rash
Counselling Points
- Monitor for hypersensitivity during infusion.
- Do not drive or operate machinery until effects are known.
Serious warnings
- Hypersensitivity reactions including anaphylaxis.
- Monitor renal function.
Important Disclaimer
The Veklury Lyophilised Powder For Iv Infusion 100 Mg 100 mg/20 ml (5 mg/ml) Powder for Injection professional information leaflet below is the property of Gilead Sciences South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
